Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Composition : Empagliflozin (25mg) + Linagliptin (5mg)
Dosage Form : Tablet
Packaging Type :
Packaging :
Price : ₹1/-
Emplozin L 25/5 Tablet is a fixed-dose combination of Empagliflozin (25mg) and Linagliptin (5mg), specifically designed for the effective management of type 2 diabetes mellitus. This dual-action therapy combines an SGLT2 inhibitor and a DPP-4 inhibitor to help control blood glucose levels, address common complications, and improve overall metabolic control.
By targeting different mechanisms, Emplozin L 25/5 Tablet provides comprehensive diabetes management, supporting better blood sugar control and enhancing overall patient outcomes.
Common side effects include upper respiratory tract infections, headache, nausea, and urinary tract infections. Serious side effects may involve kidney problems, hypotension, and dehydration.
Emplozin L 25/5 Tablet is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, particularly in patients inadequately controlled on other oral anti-diabetic therapies.
Consult your healthcare provider if you have a history of kidney disease or heart conditions before using this medication. Not recommended during pregnancy or breastfeeding.
Composition : Bromfenac (0.09% w/v) + Moxifloxacin (0.5% w/v)
Composition : Bromfenac (0.9mg)
Composition : Ketorolac (0.5% w/v)
Composition : Fluconazole (0.3% w/v)
Composition : Ketorolac (0.4% w/v) + Olopatadine (0.1% w/v)
Composition : Carboxymethylcellulose (3mg/ml) + Glycerin (10mg/ml) + n-acetylcarnosine (10mg/ml)
Composition : Dexamethasone (0.1% w/v) + Tobramycin (0.3% w/v)
Composition : Gatifloxacin (0.3% w/v)
Composition : Loteprednol etabonate (0.5% w/v)
Composition : Ketorolac (5% w/v) + Moxifloxacin (0.5% w/v)